What does it do?
GoodRx is a growth business that earns money by collecting a fee every time a consumer uses one of its discount codes to pay for a prescription at a retail pharmacy. The company sits between consumers, pharmacies, and pharmacy benefit managers (PBMs) to find the lowest available cash price for medications. When a customer uses a GoodRx code, the pharmacy pays a fee to the PBM, and the PBM then shares a portion of that fee with GoodRx. This marketplace model allows the company to offer prices that are often lower than an individual's insurance co-pay, creating a clear incentive for consumers to use the platform.
Where does revenue come from?
The majority of revenue still comes from individual prescription transactions, but the mix is rapidly shifting toward direct partnerships with drug manufacturers and recurring subscriptions. Prescription transaction revenue accounted for $106.4 million last quarter, while Pharma Direct revenue surged 76% to $61.6 million as the company helped pharmaceutical makers offer discounts on brand-name drugs directly. Subscription revenue added another $28.5 million, primarily through the GoodRx Gold program which offers deeper discounts for a monthly fee. Most of this revenue is generated within the United States market.
Revenue Breakdown
Who are its customers?
GoodRx serves nearly 25 million consumers and over one million healthcare professionals who use the platform to help patients find affordable medications. The core of the business is its 5.0 million Monthly Active Consumers who actively used a discount code at a pharmacy in the most recent quarter. Beyond these transaction-based users, the company has 764,000 active subscription plans that cover individuals and families. Healthcare professionals act as a critical distribution channel, frequently recommending the GoodRx app to patients during office visits to ensure they can afford to fill their prescribed medications.
What gives it staying power?
The company has staying power through its deep integrations with nearly all major retail pharmacies and the leading PBMs in the United States. These technical and contractual links are difficult to replicate at scale, creating a narrow moat of network effects. As more consumers use the platform, it becomes more valuable for pharmacies to participate to drive foot traffic.
Where is it headed?
The company is making a major strategic bet on becoming the primary digital channel for pharmaceutical manufacturers to offer direct-to-consumer pricing. This shift away from traditional pharmacy coupons toward manufacturer-funded savings, especially for high-cost GLP-1 weight loss drugs, is intended to insulate GoodRx from retail pharmacy store closures. Management expects this "Pharma Direct" segment to be the engine of future revenue growth and margin stability.
GoodRx is successfully pivoting its revenue mix toward high-margin segments even as its legacy transaction business faces headwinds. While total revenue was flat at $200.4 million last quarter, the triple-digit growth in Pharma Direct and 39% growth in subscriptions are replacing the declining transaction fees. This transition is essential because it moves the company toward more predictable, recurring revenue streams.
Free cash flow is significantly higher than net income, reflecting a business model with very low capital requirements. The company generated $160 million in free cash flow last year compared to just $30 million in net income, largely because it does not need to own pharmacies or physical inventory to operate its marketplace. This cash-rich profile allows for aggressive share buybacks even during periods of slow top-line growth.
The balance sheet is managed conservatively with $296 million in cash against $492 million in debt. This net debt position is manageable for a company that generates consistent cash flow, providing the flexibility to invest in new products like the Companion Family Plan. The current debt load does not pose a significant risk to operations given the company's high gross margins of 88%.
GoodRx is a financially maturing business that has transitioned from heavy losses to sustainable, cash-generating profitability.
GoodRx does not pay a dividend, focusing its cash instead on reducing debt and buying back its own stock. The company spent $14.5 million on share repurchases in the first half of 2026 as part of a broader strategy to increase the ownership slice of remaining shareholders. This buyback program is a clear sign that management views the shares as a better investment than holding excess cash.
Pharma Direct revenue grew 76% to $61.6 million, proving that drug manufacturers are willing to pay for direct access to GoodRx users. This segment bypasses the volatility of retail pharmacy closures and has become a primary driver of the company's raised full-year guidance.
Monthly Active Consumers fell to 5.0 million from 5.7 million a year ago as the retail pharmacy landscape contracts. If this user base continues to shrink, the company will struggle to maintain its leverage with PBMs and pharmaceutical partners.
The healthcare IT and prescription savings market is valued at roughly $19 billion today and is projected to reach $56 billion by 2035 as health insurance coverage slips. The industry is shifting from simple price comparison tools toward integrated health services that combine telehealth, subscriptions, and manufacturer discounts. While the sector is competitive, it remains a high-margin area because digital tools are the only way to navigate the extreme complexity of US drug pricing. GoodRx is currently the clear independent leader in this niche.
The competitive dynamic is becoming more aggressive as large retailers and insurance companies launch their own internal discount programs. Barriers to entry are moderate because a newcomer needs deep contracts with both pharmacies and PBMs to be effective. Pricing power is under constant pressure as competitors bundle prescription savings into larger ecosystems like Amazon Prime.
Amazon Pharmacy is the most dangerous threat because it can offer free home delivery and integrated discounts to over 100 million Prime members. SingleCare and Optum Perks also threaten GoodRx by competing for the same limited pool of cash-pay consumers using similar coupon-based models.
GoodRx is currently holding its ground by pivoting away from the most contested part of the market and into direct partnerships with drug makers.
The primary source of protection is the network effect created by over one million healthcare professionals who already have GoodRx integrated into their workflow. Doctors and pharmacists often default to GoodRx when a patient cannot afford a medication because it is the most recognized brand in the space. This established trust creates a distribution advantage that is difficult for a newer entrant like Amazon to quickly disrupt.
The company's 88% gross margins and consistent free cash flow prove that it still possesses a high-quality business model despite the narrow moat. The high cost of acquiring new users through search engines is the specific limit that prevents this business from having a strong or exceptional moat.
The moat direction is stable because the rapid scaling of the Pharma Direct segment is creating a new, differentiated advantage that is harder for general retailers to copy. This move deepens the company's integration with the source of the medications rather than just the retail checkout.
Recently reached net profitability but user growth has stalled year-over-year.
Repurchased $14.5M in stock and focused on paying down debt.
CEO stake is modest relative to total market cap; pay tied to performance.
Capital Allocation Track Record
Management has shown strategic judgment by pivoting the company toward manufacturer-direct and subscription revenue as the traditional coupon market becomes more commoditized. Wendy Barnes has successfully navigated the company to its first milestone of net profitability, proving that the business can be run for earnings rather than just growth. However, the consistent decline in Monthly Active Consumers suggests that the team is still searching for a way to return the core marketplace to its former scale.
The thesis is moderately dependent on the current leadership team, but the risks are balanced by an incoming CFO and a deep bench of healthcare executives. Governance is standard for a recently public company, with no immediate concerns regarding board independence or dual-class control. The main risk is the company's ability to retain talent as it competes with larger tech firms like Amazon for the engineering expertise needed to scale its digital platform.
We expect revenue to grow from $0.8B in FY2026 to $1.0B in FY2031 (~5% CAGR), with EPS growing from $0.30 to $0.60 (~15% CAGR). Growth is limited by intense competition from pharmacy benefit managers and retail giants like Amazon who are offering similar prescription discount programs. Margins improve slightly as the company reduces its reliance on expensive search engine marketing and shifts toward direct consumer relationships. EPS grows faster than revenue because the company is aggressively buying back shares and slightly improving its profit margins. Operating margin expected to reach ~13.5% by FY2031.
Dominating the direct-to-consumer GLP-1 weight loss drug distribution market. GoodRx can become the primary channel for manufacturers to offer affordable access to expensive brand-name drugs like GLP-1s.
Expansion into the employee benefits market with the Companion plan. Launching household plans as a corporate benefit in 2027 could unlock a massive, low-acquisition-cost user base.
Partnership with TrumpRx expands the cash-pay pharmacy user base. Strategic alignment with new government-led pricing platforms could significantly increase the number of users using GoodRx codes.
Amazon Pharmacy captures a significant share of the home-delivery market. If consumers move their prescription volume to Amazon for convenience, GoodRx's retail-focused marketplace will continue to shrink.
PBMs launch their own internal discount tools to bypass middlemen. If the major pharmacy benefit managers decide to capture the full fee themselves, GoodRx's transaction margins will collapse.
Continued decline in Monthly Active Consumers due to retail store closures. The physical contraction of the retail pharmacy industry is a direct threat to the distribution of GoodRx's physical discount codes.
Below is our estimate of current and future fair value, with detailed reasoning and assumptions. Fair value is a judgment, not a fact, and other analysts will likely land on different numbers. Use it as one data point in your research, and apply your own discretion in any investing decision.
A Terminal Multiple approach values the business based on its long-term profits after its current transformation into a pharmaceutical partner is finished. This method works best for GoodRx because its current earnings are being held back by heavy investments that should pay off significantly by the end of the decade. Applying a 10x multiple to the $0.60 in profit we expect by 2031 gives a future value of $6 per share, which is worth $5 today after accounting for the yearly return investors expect. We chose a 10x multiple, which is lower than health software rivals like HealthEquity (22x) or Veeva (30x) because competition from Amazon remains a serious threat to the long-term price. The $0.60 profit figure comes from our own projections of how much cash the company will keep as its Pharma Direct segment takes over.
Priced instead on next year's earnings at 15x, which is what similar healthcare services trade for, we get $5.25, which is very close to our $5 target. We used the $0.35 profit estimate for 2027 and a 15x multiple, which sits at the low end of the 15x to 25x range seen across medical information companies. This second method confirms that even without looking far into the future, the company is worth significantly more than its current $3.54 price if it hits its near-term goals.
The biggest risk is that Amazon successfully lures away enough prescription users to permanently slow down GoodRx's core coupon business. This would prevent the company from reaching its long-term profit targets, likely keeping the multiple stuck at 10x or lower and pushing the fair value down toward $3.00. Watch for any quarter where Monthly Active Consumers drop below 4.5 million as an early warning sign.
Bear case ($3): Amazon Pharmacy market share gains cause core prescription transaction revenue to drop more than 30% year-over-year; or Operating margins fall back toward 5% as marketing costs rise to defend the user base.
Bull case ($8): Pharma Direct revenue grows at 85% or higher for two consecutive years as manufacturers shift more budgets to the platform; or Monthly Active Consumers stabilize above 5.5 million and return to steady growth.
Clearthesis wrote this report from 43 sources, including SEC filings, analyst estimates, industry research, and recent news.
How did you like this thesis?
Your feedback helps us make reports better for you
© 2026 Clearthesis.ai · Report generated on October 23, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.